Genetic clues could personalize prostate cancer therapy

NCT ID NCT03348670

Ongoing Knowledge-focused Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how genetic differences (SNPs) in prostate cancer patients affect their response and side effects to the drug abiraterone. Researchers will analyze DNA from 600 patients taking abiraterone plus prednisone and bicalutamide. The goal is to find genetic markers that predict effectiveness and toxicity, which could help tailor treatment to each patient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abiraterone acetate (Zytiga) plus prednisone and bicalutamide
What this could lead to: If successful, this could help doctors predict which prostate cancer patients will benefit most from abiraterone and who might have side effects, leading to more personalized treatment.
What could go wrong: This is an observational genetic study, not a test of a new drug. It may not lead to immediate changes in treatment, and genetic markers may not reliably predict outcomes in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Medicine Invention Design, Inc. - IORG0007849 - NPI-1023387701

Rockville, Maryland, 20853, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.